Cell Cryopreservation Market Analysis

Product Segment Analysis

The cell freezing media segment in the cell cryopreservation market is projected to grow at a  share of 38.64% by 2036.  The use of specialized cell-freezing media (cryoprotectants) is a major growth lever for the cell cryopreservation market, because these media minimize ice crystal formation and osmotic damage during freezing and thawing, thereby preserving cell viability and function. DMSO penetrates cells and increases intracellular solute concentration, helping to prevent intracellular ice formation, a phenomenon well-understood in cryobiology. As demand for cell-based therapies (especially stem cells, CAR-T, etc.) rises, the requirement for GMP-grade, serum-free, defined freezing media is pushing innovation and adoption, because these formulations reduce toxicity, improve reproducibility, and meet regulatory quality standards. In short, increasing reliance on high-performance, clinically compatible freezing media is driving both the consumables (cryoprotectant solutions) and infrastructure segments of the cell cryopreservation market.

Application Segment Analysis

The stem cell banking segment in the cell cryopreservation market is expected to grow at a  share of 39.29% by 2036. Stem cell banking, particularly through cord blood units, is a critical part of modern regenerative medicine, enabling long-term storage of hematopoietic stem cells for future therapeutic use. In the U.S., the C.W. Bill Young Cell Transplantation Program’s registry maintains more than 246,500 cord blood units. Public and private banks both contribute: decades of banking have created inventories that support transplants and research, with significant government backing through programs such as the National Cord Blood Inventory (NCBI).  The genomic diversity of the banked units is increasing, which improves matching rates for patients from different ethnic backgrounds. Over 35,000 patients have benefited from cord blood transplants since the first one in 1989. Stem cell banking thus provides an essential reserve of clinically usable stem cells, fueling both life-saving therapies and long-term research into novel regenerative treatments.

End Use Segment Analysis

The biopharmaceutical & pharmaceutical companies’ segment is projected to grow at a CAGR of 19.53% in the cell cryopreservation market by the end of 2036. Biopharmaceutical and pharmaceutical companies are key end-users driving growth in the cell cryopreservation market because they develop and commercialize a growing number of advanced therapies that need robust cryostorage. According to the ASGCT-Citeline Q4 2024 report, there are 4,238 gene, cell, and RNA therapies in development, of which 2,117 (50%) involve gene-modifying or CAR-T cell approaches. The U.S. FDA has already approved multiple cellular therapies more than 40 distinct cell and gene therapy products to date.  As big pharma invests in scalable manufacturing and supply chains for these products, demand for controlled-rate freezers, validated cryobanking, and reliable cold-chain logistics surges. Moreover, regulatory support from the FDA’s CBER, including RMAT designations, provides strong incentives for these companies to adopt high-quality cryopreservation infrastructure.

Our in-depth analysis of the global cell cryopreservation market includes the following segments: